Over the past week, the FDA has published recalls for six different food products and a popular blood thinner medication in an attempt to protect the public. The dangers range from simple allergens to dangerous bacterial contaminations and improperly dosed drugs.
Companies are required to initiate recalls on their own and then notify the FDA of the action, who then publishes the information to the general public.
Here, DrugNews explains the reason for each recall, along with what consumers need to look for and what action they can take for remedies.
FDA Food Recalls
On June 7th, Florida based Global Garlic recalled 16 ounce packages of its Queso Fresco/ Whole Milk Cheese distributed in Illinois, Louisiana, Kentucky, North Carolina and Florida due to possible contamination with Listeria monocytogenes, a bacteria that can cause severe or deadly infections in children, pregnant women and the elderly.
The recalled products are marked with a UPC number 8-96211-00235-9 and an expiration date of September 19, 2017. Customers may return affected packages to the store of purchase.
On June 8th, Club Chef LLC announced a recall of ten varieties of veggie, fruit and snack trays sold under the names Fresh Selections by Kroger or Club Chef due to Listeria monocytogenes contamination.
The recalled snack kits were made on May 30 and May 31, 2017. Fortunately, no infections have yet been reported.
Also on June 8, CC Kitchens issued a recall of ten varieties of its salad and slaw kits due to possible Listeria contamination. The affected kits include the Chef, Cobb, Garden, Asian and Southwest Turkey salads, as well as Fiesta Slaw, Trial Slaw and Beef Ponzu kits.
Fortunately, no illnesses have been reported. The recalled salad and slaw kits were sold only at Kroger stores in Ohio, Michigan and West Virginia.
Yet another Listeria-based recall was issued on June 8th by Springfield, Virginia-based Happy Sprout. The company voluntarily recalled all 1 lb., 2 lb. and 10lb. packages of their GoodSeed soybean sprouts made on or after May 1, 2017 due to risks of the bacterial contamination.
Fortunately, no illnesses have been reported. The recalled sprouts were sold at retail stores in New Jersey, Maryland and Virginia and may be returned to the place of purchase for a refund.
On June 9th, Boston-based Slade Gordon issued a recall of its Gourmet Bay Toasted Crumb Tilapia, Honey Mustard Tilapia and Citrus Coconut Tilapia due to the possible presence of undeclared milk.
The affected products were packaged between January 31 and June 6 of 2017 and sold in New York, Ohio, Michigan, Pennsylvania, North Carolina, Massachusetts or Minnesota.
Finally, on June 12th Pennsylvania-based Giant Eagle issued a recall of its Market District Toasted Crumb Tilapia, Giant Eagle Toasted Crumb Tilapia and Giant Eagle Breaded Chicken Breast sold in its supermarkets, based on the earlier undeclared milk recall issued by its supplier Slade Gordon.
FDA Drug & Medical Device Warnings
On Friday, New Jersey based Bristol-Myers Squibb announced a voluntary recall of lot HN0063 of its Eliquis brand anticoagulant medication based on possible mislabeling.
Eliquis is currently the fastest growing brand of blood thinner medication, prescribed to patients with atrial fibrillation or who have recently undergone surgery in order to prevent blood clots and stroke.
The recall applies to 5 mg tablets distributed to wholesalers and retail pharmacies in the United States in February of 2017. It arose after a customer discovered a bottle labeled for Eliquis 5 mg tablets instead contained 2.5 mg tablets.
Patients who mistakenly take the reduced dose over an extended period could be at an increased risk for blood clots and stroke. However, instead of discontinuing their medication, patients are urged to talk with their doctor or pharmacist to verify their dosage.
For more information on these drug warnings and product recalls, visit the Food and Drug Administration’s website at www.FDA.gov, or contact DrugNews today.
FDA. Recalls, Market Withdrawals & Safety Alerts. (June 14, 2017). Retrieved from http://www.fda.gov/Safety/Recalls/default.htm
Despite some recent positive results from a small Parkinson’s study, the leukemia medication Tasigna from Swiss drug giant Novartis has been in the news for all the wrong reasons.
Last week, it emerged Johnson & Johnson’s Janssen unit has asked the FDA to approve expanded uses of its diabetes drug Invokana (canagliflozin), to include reducing the risk of major cardiovascular injuries and death in those with diabetes.